Senseonics sees H1 2024 net rev $10M, +21% YoY; FY 2024 guidance $22-24M

Senseonics Holdings, Inc.

Reaffirmed H1 2024 global net revenue $10M, 21% growth over H1 2023.
US new patient starts H1 2024 >200% higher than H1 2023.
FDA 510(k) for 365-day Eversense on track for Q4 2024 launch.
Mercy Health collaboration initiated; first insertions targeted Q3 2024.
FY 2024 revenue guidance $22-24M; cash utilization ~$70M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.